Brochure
15 Jul 2022

Xellia Pharmaceuticals Corporate Report 2020

PDF 2.5 MB

Committed to patients in a year impacted by COVID-19During 2020, our main focus was on maintaining full production and reliable supply of Xellia’s critical care products, while also ensuring the safety of our employees.


Read more in Xellia's Corporate Report 2020

Content provided by our supplier

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

Other Content from Xellia Pharmaceuticals ApS (5)

  • News Xellia Pharmaceuticals Cleveland, Ohio manufacturing facility commercially operational for production of key anti-infective drug products for US hospitals and patients

    Copenhagen, Denmark, and Buffalo Grove, Illinois, US, 17 August 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
  • News Cleveland, Ohio, passes FDA inspection of Injectable Drug Manufacturing Methods, Facilities, Processes & Controls

    Cleveland site to manufacture Xellia's aseptic injectables for the US market

    Copenhagen, Denmark, 26 March 2020 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received inspection sign-off from the US Food and Drug Administration (FDA) enabling the Company to commence manufacturing of drug products at its Cleveland, Ohio site.
  • Video Corporate film

    Xellia Pharmaceuticals operates internationally, with sales offices and production sites found across the globe. Xellia Pharmaceuticals is the leading supplier of important anti-infectives vancomycin, colistimethate sodium and daptomycin. We are vertically integrated from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs), with 150+ research and development scientists, and robust production sites.
  • News Xellia Pharmaceuticals Opens New Commercial Office in Dubai

    Xellia Pharmaceuticals Opens New Commercial Office in Dubai
  • Video Molecule to Market: Podcast with Carl-Åke Carlsen, CEO & President, Xellia Pharmaceuticals

    We are pleased to share the podcast: Molecule to Market – featuring our CEO, Carl-Åke Carlsson. The host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke, covering Xellia’s journey from an API supplier to a global specialty pharmaceutical company; producing anti-infective treatments. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years; offering advice and insight from his experiences. Molecule to Market is sponsored and funded by Ramarketing, an international content, design and digital agency. Click the link here to access the podcast: https://apple.co/32a0RW0 or at https://spoti.fi/3jXjgLS